



Amarin Corporation plc  
 Investor Relations Department  
 2 Pembroke House, Upper  
 Pembroke  
 Street 28-32  
 Dublin 2  
 Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AMRN**

Last Trade:	3.03
Trade Time:	4:00 PM ET Aug 21, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.56 - 4.47
Volume	N/A

Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Aug 14, 2017*  
[Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee](#)
- Aug 2, 2017*  
[Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations](#)
- Jul 26, 2017*  
[Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017](#)
- Jun 12, 2017*  
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides](#)
- Jun 1, 2017*  
[Amarin to Present at the Jefferies 2017 Global Healthcare Conference](#)

**Financials** [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)